特定のがん免疫療法を強化するために,c-MYCベースの遺伝子回路プラットフォームで腫瘍のマイクロ環境を再プログラムする
Hengji Zhan1,2,3, Hongjin Wang1,2,3, Bolin Pan1,2,3
1Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Nature communications
|August 26, 2025
まとめ
この研究は,がん免疫療法における腫瘍異質性を克服するための新しいc-MYCセンシング回路 (cMSC) とエクソソームシステム (CtC) を導入しています. このアプローチは,異常なc-MYCレベルを感知し,免疫反応を強化することで,すべての癌細胞をターゲットにします.
科学分野:
- 腫瘍学
- 免疫学
- バイオテクノロジー
背景:
- 腫瘍内異質性 (ITH) は,抗腫瘍免疫反応に影響を及ぼし,がん免疫療法において重要な課題となっている.
- 細胞MYC (c-MYC) は,ITHの進行を指揮する上で重要な役割を果たし,治療戦略の重要なターゲットとなっています.
研究 の 目的:
- 異常なc-MYCレベルをターゲットに ITHを克服する新しい治療プラットフォームを開発する.
- 腫瘍内の細胞間通信を強化し 癌細胞を全面的に標的とするシステムを設計する.
- 腫瘍細胞を再プログラムして 抗腫瘍免疫反応を刺激することで 癌の免疫療法を強化します
主な方法:
- c-MYCベースのセンシング回路 (cMSC) の開発は,異常なc-MYCレベルによって活性化されます.
- 細胞対細胞 (CtC) システムを導入し,すべての腫瘍細胞の通信と標的を強化する.
- 腫瘍の微小環境を再構成する 免疫刺激剤を発現させるように 癌細胞を再プログラムする
主要な成果:
- cMSC/CtCプラットフォームは,がん細胞の異常なc-MYC発現を成功裏に検出します.
- 設計されたシステムは 腫瘍内のすべての細胞を効果的に標的とし ITHによって課される制限を回避します
- 免疫刺激剤の発現により,T細胞媒介による腫瘍解離が強化され,腫瘍の微小環境が再構築されました.
結論:
- 開発されたcMSC/CtCプラットフォームは,c-MYCを正確に検知することで,がん免疫療法のための有望な戦略を提供します.
- このアプローチは,ITHによって引き起こされる課題を効果的に克服し,強力な免疫療法反応をもたらします.
- 異常なc-MYCレベルをターゲットにすることで,より効果的ながん治療の開発に有効な道を示しています.
関連する概念動画
Tumor Immunotherapy
660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
Induced Pluripotent Stem Cells
4.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.4K
The Tumor Microenvironment
6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Somatic to iPS Cell Reprogramming
2.3K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.3K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K


